Recombinant Anti-Integrin beta 3 antibody [Y2/51] (ab9509)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Mouse monoclonal [Y2/51] to Integrin beta 3
- Suitable for: Flow Cyt
- Reacts with: Human
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-Integrin beta 3 antibody [Y2/51]
See all Integrin beta 3 primary antibodies -
Description
Mouse monoclonal [Y2/51] to Integrin beta 3 -
Host species
Mouse -
Tested applications
Suitable for: Flow Cytmore details
Unsuitable for: ICC/IF,IHC-P or WB -
Species reactivity
Reacts with: Human -
Immunogen
Tissue, cells or virus corresponding to Human Integrin beta 3. PHA-stimulated human mononuclear cells.
-
Positive control
- Flow cyto: Human peripheral blood mononuclear cell (PBMC) cells
-
General notes
This product has been switch from hybridoma to recombinant on 25th March 2024.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 0.05% BSA, 40% Glycerol (glycerin, glycerine), 59% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
Y2/51 -
Myeloma
unknown -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab9509 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
1/1000.
|
Notes |
---|
Flow Cyt
1/1000. |
Target
-
Function
Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Tissue specificity
Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis. -
Involvement in disease
Defects in ITGB3 are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors. -
Sequence similarities
Belongs to the integrin beta chain family.
Contains 1 VWFA domain. -
Post-translational
modificationsPhosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 3690 Human
- Omim: 173470 Human
- SwissProt: P05106 Human
- Unigene: 218040 Human
-
Alternative names
- BDPLT16 antibody
- BDPLT2 antibody
- CD 61 antibody
see all
Images
-
Flow cytometric analysis of Human peripheral blood mononuclear cell (PBMC) cells labelling Integrin beta 3 with ab9509 at 1/1000 dilution (0.1 ug) / Right compared with a Mouse monoclonal IgG / Left.
Goat anti mouse IgG (Alexa Fluor® 488, ab150113) was used as the secondary antibody at 1/2000 dilution.
Cells were stained with mouse IgG or ab9509. Then stained with anti-CD41 conjugated to APC.
Gated on viable cells. -
Flow cytometric analysis of HeLa (Human cervix adenocarcinoma epithelial cell, Left) / HUVEC (Human umbilical vein endothelial cell, Right) cells labelling Integrin beta 3 with ab9509 at 1/1000 dilution (0.1 ug)/Red compared with a Mouse monoclonal IgG / Black isotype control and an unlabelled control (Cell without incubation with primary antibody and secondary antibody / Blue).
Secondary antibody was Goat anti mouse IgG (Alexa Fluor® 488, ab150113) used at 1/2000 dilution.
Negative control: HeLa.
Gated on viable cells.
Datasheets and documents
-
Datasheet download
References (0)
ab9509 has not yet been referenced specifically in any publications.